| P50 | author | Corneliu Lungoci | Q41708062 |
| P2093 | author name string | Pompiliu Piso | |
| | Max Mayr | |
| | Valentin Muntean | |
| | Hubert Leebmann | |
| | Aurel Ion Mironiuc | |
| | Traian Oniu | |
| P2860 | cites work | The role of prophylactic hyperthermic intraperitoneal chemotherapy in the management of serosal involved gastric cancer | Q95576013 |
| | The use of quinacrine hydrochloride for the control of malignant serous effusions | Q70541023 |
| | Volume determination of ascites using intraperitoneal bromsulphalein administration | Q70699807 |
| | The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies | Q71415334 |
| | Dissection by electrocautery with a ball tip | Q72123183 |
| | Hyperthermia: has its time come? | Q73223658 |
| | Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study | Q73368601 |
| | Peritoneal carcinomatosis from colorectal cancer | Q78553388 |
| | Hemisulfur mustard in the palliation of patients with metastatic ovarian carcinoma | Q78615260 |
| | Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis | Q78743915 |
| | Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer | Q79150738 |
| | Evaluation of the risk of contamination of surgical personnel by vaporization of oxaliplatin during the intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) | Q80098613 |
| | [Clinical practice guideline on peritoneal carcinomatosis treatment using surgical cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy] | Q80276078 |
| | Cost-effectiveness of intraperitoneal chemohyperthermia in the treatment of peritoneal carcinomatosis from colorectal cancer | Q81303388 |
| | Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from gastric cancer | Q82443706 |
| | Pont hepatique (hepatic bridge), an important anatomic structure in cytoreductive surgery | Q82549171 |
| | Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results | Q83440316 |
| | Outcomes associated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in colorectal cancer patients with peritoneal surface disease and hepatic metastases | Q84008398 |
| | Comparison of optimally resected hepatectomy and peritonectomy patients with colorectal cancer metastasis | Q84443981 |
| | A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis | Q84567602 |
| | Evolution of cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: are there treatment alternatives? | Q85092366 |
| | Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology | Q85263926 |
| | HIPEC: standard of care or an experimental approach? | Q85333204 |
| | Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin | Q86949298 |
| | Controversy and consensus on the management of patients with pseudomyxoma peritonei | Q87235005 |
| | Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial | Q87416761 |
| | Feasibility of adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in a short stay setting in patients with colorectal cancer at high risk of peritoneal carcinomatosis | Q87466537 |
| | [Cytoreductive surgery for malignant peritoneal tumors] | Q87659907 |
| | When are randomised trials unnecessary? Picking signal from noise | Q24673438 |
| | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Q28036747 |
| | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology | Q33262026 |
| | Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin | Q33777576 |
| | Metastatic colorectal cancer: survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy | Q33850248 |
| | It's what the surgeon doesn't see that kills the patient | Q33897621 |
| | Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 |
| | Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases | Q33931049 |
| | Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases | Q34003396 |
| | Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer | Q34055165 |
| | Clinical delivery system for intraperitoneal hyperthermic chemotherapy. | Q34268781 |
| | Peritonectomy procedures | Q34316366 |
| | Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone | Q34354500 |
| | New approach to peritoneal surface malignancies | Q34391069 |
| | Hyperthermic intraperitoneal chemotherapy: Rationale and technique | Q34391107 |
| | A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial | Q34580450 |
| | Systematic review of intraperitoneal chemotherapy for gastric cancer | Q34629897 |
| | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial | Q34928467 |
| | Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation | Q35072551 |
| | Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). | Q35085352 |
| | GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. | Q35120716 |
| | Natural history of peritoneal carcinomatosis from nongynecologic malignancies. | Q35563265 |
| | Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis | Q35563273 |
| | Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. | Q35721069 |
| | Small bowel involvement is a prognostic factor in colorectal carcinomatosis treated with complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy | Q35930429 |
| | Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC. | Q35974935 |
| | Implantation Peritoneal Carcinomatosis of Ovarian Origin. | Q36114521 |
| | Systemic Chemotherapy prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term Survival | Q36140934 |
| | How do cells respond to their thermal environment? | Q36336615 |
| | Introduction of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) to the surgery program | Q44038189 |
| | Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro | Q44038376 |
| | The St George Hospital Peritoneal Surface Malignancy Program--where are we now? | Q44064729 |
| | Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study | Q44393228 |
| | Thermal Enhancement of New Chemotherapeutic Agents at Moderate Hyperthermia | Q44431967 |
| | Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials | Q44880937 |
| | Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin | Q44892132 |
| | Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance | Q45059053 |
| | Hyperthermic intraperitoneal chemotherapy during primary tumour resection limits extent of bowel resection compared to two-stage treatment | Q45113550 |
| | Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. | Q45341695 |
| | The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. | Q45823091 |
| | Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases | Q45868124 |
| | Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres | Q47216330 |
| | Circumferential cutaneous traction for exposure of the layers of the abdominal wall | Q47365546 |
| | Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C. | Q51177063 |
| | Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. | Q51637241 |
| | Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. | Q51742663 |
| | Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. | Q53286355 |
| | The subpyloric space: an important surgical and radiologic feature in pseudomyxoma peritonei. | Q53676650 |
| | Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. | Q53877416 |
| | Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia. | Q54270096 |
| | Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. | Q54308984 |
| | Genitourinary resection at the time of cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis is not associated with increased morbidity or worsened oncologic outcomes: a case-matched study. | Q54466584 |
| | Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin | Q57108862 |
| | Results of Systematic Second-Look Surgery in Patients at High Risk of Developing Colorectal Peritoneal Carcinomatosis | Q60629685 |
| | Implementation of a Standardized HIPEC Protocol Improves Outcome for Peritoneal Malignancy | Q61182940 |
| | Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors | Q69935981 |
| | Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. | Q36571925 |
| | A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma | Q36665886 |
| | Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer | Q36818968 |
| | A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. | Q36892244 |
| | Physicians' awareness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer carcinomatosis | Q37057229 |
| | Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol | Q37308110 |
| | The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis. | Q37427706 |
| | A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin | Q37478215 |
| | Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality | Q37498106 |
| | Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy | Q37512841 |
| | Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma | Q37526718 |
| | Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future | Q37583768 |
| | Management of colorectal liver metastases in patients with peritoneal carcinomatosis. | Q37583772 |
| | Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients | Q37662806 |
| | Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) | Q37698285 |
| | Surgical responsibilities in the management of peritoneal carcinomatosis | Q37761703 |
| | Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity | Q37895575 |
| | Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review | Q38054557 |
| | Surgical management of colorectal peritoneal metastases: treatment and outcomes compared with hepatic metastases. | Q38058707 |
| | Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies | Q38067847 |
| | Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. | Q38158998 |
| | Repeat cytoreductive surgery (CRS) for recurrent colorectal peritoneal metastases: yes or no? | Q38174700 |
| | Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. | Q38199370 |
| | The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art. | Q38201470 |
| | The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis | Q38214032 |
| | Treatment of ovarian cancer with thiotepa. | Q39877351 |
| | Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study | Q39928697 |
| | Hepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | Q40344591 |
| | Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. | Q40355978 |
| | Metastatic inefficiency: the scientific basis for resection of liver metastases from colorectal cancer | Q40912670 |
| | Cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer: a new standard of care or an experimental approach? | Q41902566 |
| | PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER | Q41902598 |
| | Postoperative infections after cytoreductive surgery and HIPEC for peritoneal carcinomatosis: proposal and results from a prospective protocol study of prevention, surveillance and treatment | Q42240207 |
| | Comparison of prognostic scores for patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy | Q42615377 |
| | Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. | Q43130795 |
| | Morbidity and mortality of hyperthermic intraperitoneal chemoperfusion | Q43580584 |
| | Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. | Q43932503 |
| | 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer | Q43941230 |
| | Intrapleural and intraperitoneal instillation of nitrogen mustard in palliative treatment of malignant effusions | Q43981400 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | peritoneal carcinomatosis | Q2071182 |
| P304 | page(s) | 67-82 | |
| P577 | publication date | 2016-01-15 | |
| P1433 | published in | World journal of gastrointestinal oncology | Q27723329 |
| P1476 | title | Multimodality treatment strategies have changed prognosis of peritoneal metastases | |
| P478 | volume | 8 | |